Docetaxel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals

Drug Profile

Docetaxel nanosomal - Intas Pharmaceuticals/Jina Pharmaceuticals

Alternative Names: DoceAqualip; Nanosomal docetexal

Latest Information Update: 18 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intas Pharmaceuticals; Jina Pharmaceuticals
  • Developer Intas Pharmaceuticals; Jina Pharmaceuticals; University of Southern California
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Head and neck cancer; Prostate cancer
  • Phase I Solid tumours

Most Recent Events

  • 14 Jul 2016 Jina Pharmaceuticals completes a phase I trial in Solid tumours (Late-stage disease) in USA (IV, Infusion) (NCT01957995)
  • 21 Oct 2015 Launched for Gastric cancer in India (IV) before October 2015
  • 21 Oct 2015 Launched for Head and neck cancer in India (IV) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top